Jason Russell
About Jason Russell
Jason Russell is the Director of Strategic Accounts at Aimmune Therapeutics, where he has worked since 2019. He has extensive experience in the pharmaceutical industry, with expertise in various therapy areas and a history of roles at notable companies such as Sandoz, Novartis, Pfizer, and Bioverativ.
Current Role at Aimmune Therapeutics
Jason Russell serves as the Director of Strategic Accounts at Aimmune Therapeutics, a position he has held since 2019. In this role, he focuses on developing strategies that enhance physician and patient access to national specialty pharmacies. His work involves leveraging insights from the healthcare sector to drive sales and profitability.
Previous Experience at Sandoz
Before joining Aimmune Therapeutics, Jason Russell worked at Sandoz as the Associate Director of National Accounts – Specialty Pharmacy from 2015 to 2017. His tenure at Sandoz, based in Princeton, NJ, involved managing national accounts and developing strategies to improve market access for specialty pharmacy products.
Expertise in Therapy Areas
Jason Russell has extensive expertise in various therapy areas, including hemophilia, rare diseases, dermatology, multiple sclerosis, and rheumatology. His knowledge in these fields supports his ability to provide valuable insights that translate into effective sales strategies and market growth.
Educational Background
Jason Russell earned a Bachelor of Science (B.S.) degree in Psychology from California Lutheran University, where he studied from 1989 to 1993. This educational background contributes to his understanding of healthcare dynamics and patient interactions.
Career Progression and Roles
Throughout his career, Jason Russell has held several key positions in the pharmaceutical industry. He worked at Novartis in various roles, including Business Relationship Manager and Senior Regional Account Manager, from 2000 to 2015. He also served as an Institutional Representative at Pfizer from 1994 to 2000 and as National Account Manager at Bioverativ, a Sanofi company, from 2017 to 2019.